ANAB Earnings & Financial Statements
AnaptysBio, Inc.
$48.73
+$0.63(+1.31%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
468.09K
52W Range
$30.27 - $73.30
Target Price
--
ANAB earnings and financial statements: AnaptysBio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ANAB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $234.60M | $91.28M | $17.16M | $10.29M | $63.17M |
| Operating income | $47.90M | -$114.95M | -$164.41M | -$115.15M | -$56.81M |
| EBITDA | -$10.64M | -$142.83M | -$161.25M | -$105.26M | -$54.26M |
| Net income | -$13.23M | -$145.23M | -$163.62M | -$128.72M | -$57.80M |
| EPS (diluted) | $-0.46 | $-5.12 | $-6.08 | $-4.57 | $-2.11 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $364.39M | $483.83M | $452.39M | $610.38M | $643.07M |
| Total liabilities | $50.66M | $59.54M | $364.29M | $348.28M | $286.64M |
| Shareholders’ equity | $37.21M | $70.87M | $88.10M | $262.10M | $356.43M |
| Cash and equivalents | $238.20M | $123.08M | $35.97M | $71.31M | $495.73M |
| Long-term debt | $12.03M | $14.11M | $16.04M | $17.81M | $19.45M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $19.70M | -$135.34M | -$120.80M | -$73.59M | -$45.92M |
| Capital expenditure | -$87.0K | -$358.0K | -$807.0K | -$358.0K | -$1.37M |
| Free cash flow | $19.61M | -$135.69M | -$121.61M | -$73.95M | -$47.29M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANAB | $48.73 | +1.3% | 468.09K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |